rs1555509569
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_004960.4(FUS):c.1394-2delA variant causes a splice acceptor, intron change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. 1/1 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_004960.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Publications
- amyotrophic lateral sclerosisInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, Illumina
- amyotrophic lateral sclerosis type 6Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, ClinGen
- juvenile amyotrophic lateral sclerosisInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- tremor, hereditary essential, 4Inheritance: AD, Unknown Classification: LIMITED Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:2
- -
- -
FUS-related disorder Pathogenic:1
The FUS c.1394-2delA variant is predicted to result in a deletion affecting a canonical splice site. This variant has been reported in individuals with amyotrophic lateral sclerosis (ALS, Table 2, Cady et al. 2015. PubMed ID: 25382069) and frontotemporal dementia (FTD, Table S1, Wagner et al. 2021. PubMed ID: 34561610). It has also been reported to have arisen de novo in a Chinese individual with ALS (Figure 1, Yang et al. 2023. PubMed ID: 36511129). RNA sequencing analysis confirmed that this variants results in exon 14 skipping and premature protein termination (Figure 1, Yang et al. 2023. PubMed ID: 36511129). Additional immunofluorescence studies have found that this variant leads to abnormal protein localization in the cytoplasm, likely due to the loss of the C-terminal nuclear localization signal (Figure 2, same study). This variant has not been reported the gnomAD database, indicating this variant is rare. Of note, additional splice-altering variants at the same acceptor site have been reported in individuals with ALS (c.1394-2A>G, DeJesus-Hernandez et al. 2010. PubMed ID: 20232451; c.1394-1G>T, Tunca et al. 2020. PubMed ID: 32579787; c.1394-1G>C, Chen et al. 2022. PubMed ID: 34544842). Loss of function variants in FUS are expected to be pathogenic. Taken together, the c.1394-2delA variant is interpreted as pathogenic. -
Amyotrophic lateral sclerosis type 6 Pathogenic:1
- -
Amyotrophic lateral sclerosis type 6;C3539195:Tremor, hereditary essential, 4 Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 447355). Disruption of this splice site has been observed in individuals with early-onset amyotrophic lateral sclerosis (PMID: 20232451, 25382069). This variant is not present in population databases (gnomAD no frequency). This sequence change affects a splice site in intron 13 of the FUS gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in FUS are known to be pathogenic (PMID: 20660363, 23217123). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at